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PRL-3 Promotes the Malignant Progression of
Melanoma via Triggering Dephosphorylation and
Cytoplasmic Localization of NHERF1
Xian-Ying Fang1,3, Ran Song1,3, Wei Chen1, Yuan-Yuan Yang1, Yan-Hong Gu2, Yong-Qian Shu2,
Xu-Dong Wu1, Xue-Feng Wu1, Yang Sun1, Yan Shen1 and Qiang Xu1
Phosphatase of regenerating liver-3 (PRL-3) has been reported to have a critical role in metastatic progression of
cancers. Here, we investigate how PRL-3 increases the malignant degree of melanoma cells. The expression of
PRL-3 increased gradually during the malignant progression of melanoma. The phosphorylation of Akt was
elevated in highly malignant melanoma cells, which was accompanied by a decrease in nuclear phosphatase and
tensin homolog (PTEN). The phosphorylation of NHERF1 in the serine site was regulated by PRL-3 and showed
cytoplasmic translocation upon dephosphorylation, which resulted in a decrease in nuclear PTEN. The co-
translocation of NHERF1 and PTEN from the nucleus to the cytoplasm was observed during the malignant
progression of melanoma cells. Tumor growth was inhibited signiﬁcantly, and the survival was prolonged upon
knockdown of cytoplasmic NHERF1 in B16BL6 cells prior to the inoculation into mice. Taken together, to our
knowledge previously unreported, we have identiﬁed NHERF1 as a potential substrate of PRL-3. Its
phosphorylation status as well as its change in cellular localization and association with PTEN correlated with
the malignant progression of melanoma. Our data provide an explanation for how PRL-3 promotes the malignant
progression of melanoma, as well as a diagnostic marker or therapeutic target for malignant melanoma.
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INTRODUCTION
Melanoma, a malignant tumor of melanocytes, can be very
serious if not diagnosed early (Nikolaou et al., 2012). The
elevated expression of phosphatase of regenerating liver-3
(PRL-3) was shown to be associated with the increased
metastatic potential and the poor prognosis of human cancers
(Al-Aidaroos and Zeng, 2010; Wang and Lazo, 2012). Our
previous studies have indicated that highly metastatic B16BL6
melanoma cells express more PRL-3 than lowly metastatic
B16F1 cells (Wu et al., 2004). Furthermore, the downregulation
of PRL-3 inhibits the growth and metastasis of melanoma (Qian
et al., 2007; Wang et al., 2009). However, the underlying
mechanisms of PRL-3-promoted metastasis remain unclear.
Ezrin, Keratin 8, and integrin β1 are reported to be
dephosphorylated by PRL-3 (Forte et al., 2008; Mizuuchi
et al., 2009; Tian et al., 2012). Recent research shows that
PRL-3 serves as a regulator of H3K9 methylation during the
progression of colorectal carcinoma (Liu et al., 2013). In
addition, several studies have revealed that PRL-3 seems to
activate the PI3K/Akt signaling pathway (Wang et al., 2007;
Wang et al., 2010; Jiang et al., 2011), which is usually
hyperactivated in tumor cells (Fang et al., 2013). However,
phosphatase and tensin homolog (PTEN), another important
phosphatase, functions as a tumor suppressor by negatively
regulating the PI3K/Akt signaling pathway (Parapuram et al.,
2011). Over the last few years, a variety of proteins have been
identiﬁed to interact with PTEN and to regulate its function,
including controlling its localization (Feng et al., 2008;
van Diepen et al., 2009; Zhang and Yu, 2010). Nuclear-
cytoplasmic compartmentalization may be an important
mechanism in the regulation of PTEN’s biological function
(Ming and He, 2009).
NHERF1/EBP50 (Na+/H+ exchanger regulating factor 1;
ezrin-radixin-moesin binding phosphoprotein of 50 kDa) is a
PDZ domain–containing protein (Georgescu et al., 2008).
NHERF1 seems to act as a tumor suppressor when localized at
the apical level of the cell membrane but as an oncogenic
protein when localized in the cytoplasm or the nucleus
(Shibata et al., 2003; Mangia et al., 2009; Hayashi et al.,
2010; Malfettone et al., 2012; Mangia et al., 2012). It has
been both predicted and experimentally veriﬁed that NHERF1
function is determined by the residues on which it is
ORIGINAL ARTICLE
1State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences,
Nanjing University, Nanjing, China and 2Department of Clinical Oncology, The
First Afﬁliated Hospital with Nanjing Medical University, Nanjing, China
Correspondence: Yang Sun or Yan Shen or Qiang Xu, State Key Laboratory of
Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University,
Nanjing 210093, China. E-mail: yangsun@nju.edu.cn or shenyan@nju.edu.cn
or molpharm@163.com
3These authors contributed equally to this work.
Received 23 October 2014; revised 7 April 2015; accepted 8 April 2015;
accepted article preview online 21 April 2015; published online 14 May 2015
© 2015 The Society for Investigative Dermatology www.jidonline.org 2273
phosphorylated (Chen et al., 2012; Sun et al., 2013).
However, little is known about the relationship between the
phosphorylation of NHERF1 and the malignant progression of
tumor cells.
Comparative studies are often used to identify key
regulatory molecules in tumor growth and progression (Yang
et al., 2004). Here, we performed a systematic study to
investigate the relationship between PRL-3 and NHERF1 in
the malignant progression of melanoma by using a series of
melanoma cell lines with different degrees of malignancy and
human melanoma samples of different stages. The phosphory-
lation status, change in cell translocation, and association of
NHERF1 with PTEN were kinetically examined to provide a
deeper explanation for how PRL-3 promotes the malignant
progression of melanoma.
RESULTS
Metastatic generation–related increases in proliferation,
adhesion, migration, invasion, spontaneous metastasis, as well
as PRL-3 expression of murine B16 melanoma cells during
malignant progression
To examine the malignant progression of melanoma cells, we
established a series of sub-cell lines, B16F2-F10, with a
successively progressed malignancy from low-metastatic
murine melanoma B16F1 cells by an in vivo repeated inocu-
lation approach. As expected, the cell growth rate increased
in a malignancy-dependent manner from B16F1 to F10, and
highly metastatic B16BL6 grew fastest in vitro (Supplementary
Figure S1a online). We selected three cell lines B16F1,
B16F10, and B16BL6 to evaluate their adhesive capabilities
and their migratory and invasive capabilities. Both B16F10
and B16BL6 cells exhibited a signiﬁcant increase in their
ability to adhere to ﬁbronectin compared with B16F1 cells
(Supplementary Figure S1b online). Similar to the results of the
adhesion assay, 2.23 and 3.76 times more B16F10 and
B16BL6 cells, respectively, migrated to the undersurface in
the migration assay compared with B16F1 cells. B16F10 and
B16BL6 cells were 1.29 and 1.97 times more invasive,
respectively, compared with B16F1 cells, as measured by the
proportion of cells traversing the matrigel in the invasion
assay (Supplementary Figure S1c and f online).
As shown in Figure 1a, the expression of PRL-3 was
gradually elevated along with the increase in B16 cell
generations. To conﬁrm the impact of PRL-3 on melanoma
metastasis in vivo, we constructed a spontaneous meta-
stasis model using B16F10-luc cells stably transfected with
luciferase. B16F10-luc cells were transfected with a PRL-3-
expressing plasmid or PRL-3 siRNA and then injected sub-
cutaneously into the footpads of C57BL/6 mice (Figure 1b).
Live bioluminescence imaging revealed that tumor metastasis
from footpad to draining lymph nodes was greatly promoted
by PRL-3 overexpression, whereas reduced by PRL-3 knock-
down compared with controls (Figure 1c). Accordingly, the
draining popliteal lymph nodes from the mice implanted with
PRL-3 overexpressing B16F10-luc cells showed higher ratios
of visible metastasis than controls, whereas those from the
mice implanted with PRL-3 knockeddown cells were oppo-
site (Figure 1d). Taken together, the results suggest that
progressively elevated PRL-3 levels could drive the malignant
development of melanoma.
To rule out off-target effects, a second nonoverlapping
siRNA special for human PRL-3 was used in the cell invasion
assay and inhibited the metastasis of human melanoma cells
(Supplementary Figure S1g online).
The difference in malignancy between B16F1 and B16BL6 is
relative to the level of Akt phosphorylation and the phosphatase
activity of PTEN
We selected B16F1 and B16BL6 cells and examined the status
of their Akt signaling pathway. The phosphorylation level
of Akt was higher in B16BL6 cells than that in B16F1 cells,
but there was no difference in the expression of total Akt
(Supplementary Figure S2a online). Treatment with Akt
inhibitor abrogated the difference in the growth rate between
the two cell lines, suggesting the possible involvement of Akt
signaling in the malignant progression from B16F1 to B16BL6
cells (Supplementary Figure S2b online). When the upstream
molecules of the Akt signaling pathway were examined, no
signiﬁcant difference was found in the levels of either total or
phosphorylated PDK1, mTOR, PI3K subunit p110, or PTEN
between the two cell lines (Supplementary Figure S2c online).
To exclude the possibility of PTEN mutation, PTEN mRNA
was extracted for sequencing analyses. The PTEN sequence in
the two cell lines was identical to NCBI Data Base (data not
shown). Three siRNAs for PTEN were designed, and the most
effective of them, PTEN-siRNA-1, was used in the following
experiments (Supplementary Figure S3a online). When PTEN
expression was knocked down by PTEN siRNA, the level of
phosphorylated Akt (pAkt) specially in the nucleus was
increased markedly in B16F1 cells but slightly in B16BL6 cells
(Figure 2a). Treatment with PTEN inhibitor, bpV (Hopic), also
caused the elevation of pAkt (Supplementary Figure S2d
online), suggesting that PTEN negatively regulated Akt phos-
phorylation more actively in B16F1 cells than in B16BL6 cells.
PTEN accompanied with NHERF1 translocates from nucleus to
the cytoplasm in melanoma cells during malignant progression
NHERF-1 has been reported to interact with PTEN, and the
interaction is essential for the phosphatase activity of PTEN in
normal cells (Takahashi et al., 2006). B16BL6 cells were co-
transfected with HA-NHERF1 and Flag-PTEN-WT (wild type)/
Flag-PTEN-△PDZ (PDZ-domain deletion mutation) vectors.
An IP assay showed that NHERF1 interacted with PTEN via
the PDZ binding domain of PTEN (Figure 2b). Interestingly, IF
colocalization experiments revealed that the endogenous
NHERF1 and PTEN accumulated mostly in the nucleus of
B16F1 cells (Figure 2c). By contrast, NHERF1 and PTEN were
diffuse in both the nucleus and cytoplasm of B16F10 cells
and accumulated mostly in the cytoplasm of B16BL6 cells.
The expression of cytoplasmic or nuclear NHERF1 and PTEN
as determined by WB conﬁrmed the trafﬁcking direction of
NHERF1 and PTEN from the nucleus to the cytoplasm during
the malignant progression of melanoma cells (Supplementary
Figure S4a and c online).
Similar results were obtained from the 231 human
malignant melanoma samples (Figure 2d). NHERF1 localized
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to the nucleus of 60, 22.3, and 27.3% of stage I, II, and III
melanoma, respectively. NHERF1 could not be detected in
the nucleus of stage IV or lymph node metastatic melanoma.
By contrast, NHERF1 was present in the cytoplasm of 10.6,
18.2, 57.1, and 60.6% of stage II, III, IV, and lymph node
metastatic melanoma, respectively. No NHERF1 was found in
the cytoplasm in stage I melanoma. By an analysis of human
melanoma tissues from patients in stage I and lymph node
metastasis, we found that NHERF1 and PTEN colocalized in
the nucleus in stage I melanoma. However, such colocaliza-
tion shifted to the cytoplasm in lymph node metastatic
melanoma (Supplementary Figure S4d online). The results
reﬂect a consistency in the trafﬁcking direction of NHERF1
and PTEN between the successively progressed melanoma
cell lines and human malignant melanoma with progressive
clinical stages.
Cytoplasmic NHERF1 promotes Akt activation dependently on
the phosphatase activity of PTEN
To address the question of whether the change of NHERF1
localization has any effect on the phosphorylation of Akt, we
examined the effect of NHERF1 knockdown on PTEN
localization in B16BL6 cells transfected with NHERF1 siRNA.
The most effective and speciﬁc NHERF1-siRNA-1 was used
(Supplementary Figures S3b and c online). As shown in
Figure 4a, the expression of NHERF1 siRNA resulted in the
translocation of PTEN from the cytoplasm to the nucleus.
With the accumulation of nuclear PTEN, the level of pAkt in
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Figure 1. Phosphatase of regenerating liver-3 (PRL-3) promotes the metastasis of melanoma cells. (a) The protein levels of PRL-3 were compared among
a series of B16 melanoma cells by WB. (b) The PRL-3 levels in B16F10-luc cells were detected 48 hours after PRL-3 overexpression (pTARGET-Myc-PRL-3)
or interference (pRNA-U6.1/Neo-Luc-PRL-3-siRNA). (c) Treated B16F10-luc cells (5× 105 cells) were injected subcutaneously into the right footpads of
C57BL/6 mice (n=6), respectively. In vivo ﬂuorescent imaging of all mice was taken 20 days after injection, and the luminescence statistics of the near-end
lymph node metastasis were shown. (d) The draining popliteal lymph nodes from the injected footpads. In all WB, the relative band density was analyzed
using Image J. Data are the mean+/− SEM of three independent experiments. *Po0.05 and **Po0.01.
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the nucleus decreased signiﬁcantly (Figure 3b). Furthermore,
the decrease in pAkt caused by NHERF1 siRNA was nearly
reversed by the pretreatment of B16BL6 cells with the PTEN
inhibitor, bpV (Figure 3c). Similarly, the phosphorylation of
Akt, which was stimulated by FBS after serum-deprivation,
was reduced by NHERF1 siRNA, and it was reversed by
treatment of B16BL6 cells with bpV (Figure 3d). These results
suggest that the amount of PTEN in the nucleus, which can be
regulated by NHERF1, determines the activation of Akt.
PRL-3 regulates the phosphorylation of NHERF1 at Ser residue
and promotes the translocation of NHERF1 from the nucleus
to the cytoplasm
On the basis of the ﬁndings described above, we reasoned
that progressively elevated PRL-3 levels might account for the
trafﬁcking direction of NHERF1 and PTEN from the nucleus to
the cytoplasm during the malignant progression of melanoma
cells. Thus, we transfected B16F1 cells with a PRL-3-
expressing plasmid, or we transfected B16BL6 cells with
PRL-3 siRNA. IF colocalization experiments revealed that
PRL-3 overexpression promoted the translocation of NHERF1
and PTEN from the nucleus to the cytoplasm, whereas PRL-3
interference led to the nuclear retention of NHERF1
(Figure 4a). WB results conﬁrmed the effect of PRL-3 on the
intracellular distribution of NHERF1 and PTEN (Figure 4b).
The experiment in B16F10 cells showed the same results
(Supplementary Figures S5a online). When human melanoma
A375 (PRL-3 low) and A875 (PRL-3 high) cells were treated
with PRL-3 overexpression or interference, respectively,
similar results were obtained (Figure 4c and d). To further
conﬁrm the proposed PRL-3-NHERF1-PTEN circuitry, co-
perturbation experiments such as siPRL-3/siNHERF1 and over-
expression PRL-3/siNHERF were taken as shown in Figure 4e.
When B16F1 and B16BL6 cells were co-perturbed with NHERF
siRNA, the cytoplasm–nucleus translocation of NHERF1 and
PTEN triggered by PRL-3 was inhibited.
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Figure 2. NHERF1 colocalizes with phosphatase and tensin homolog (PTEN) and inﬂuences the phosphorylation of Akt. (a) The phosphorylation of
Akt in the cytoplasm and the nucleus of B16F1 and B16BL6 cells was detected by WB after treatment with synthetic PTEN-siRNA. (b) B16BL6 cells were
cotransfected with HA-NHERF1 and Flag-PTEN-WT or Flag-PTEN-ΔPDZ expression vector. Twenty-four hours after transfection, the interaction between
NHERF1 and PTEN was detected by IP (left panel). The endogenous interaction between NHERF1 and PTEN in B16BL6 cells was detected by IP (right panel).
(c) Endogenous NHERF1 (red) and PTEN (green) were detected by confocal immunoﬂuorescence microscopy. The overlay is indicated in yellow. (d) Parafﬁn
sections of human melanoma were stained with anti-NHERF1 antibody followed by hematoxylin staining. Statistical analysis of NHERF1 localization in
human melanoma samples through the IHC assay of melanoma tissue arrays (n=231). Cyt, cytoplasm; Nuc, nucleus. Data are the mean+/-SEM of three
independent experiments. *Po0.05 and **Po0.01. Scale bar= 50 μm.
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Because PRL-3 is a phosphatase and NHERF1 can be
phosphorylated at multiple serine and threonine residues
(Chen et al., 2012), we compared the phosphorylation levels
of NHERF1 in B16F1 and B16BL6 cells. The anti-p-Ser and
anti-p-Thr antibodies were used to detect the phosphorylation
of NHERF1 indirectly after NHERF1 was immunoprecipitated.
The levels of phosphorylated NHERF1(Ser) were much higher
in B16F1 cells than they were in B16BL6 cells, whereas no
signiﬁcant change in the phosphorylation status of NHERF1
(Thr) was found in either cell line (Figure 5a). Furthermore,
the levels of phosphorylated NHERF1(Ser) were detected in
the nucleus of B16F1 cells, whereas it was barely detected
in either the nucleus or the cytoplasm of B16BL6 cells
(Figure 5b). These ﬁndings suggest that the subcellular
localization of NHERF1 is dependent on its phosphorylation
status.
To further determine whether the levels of phosphorylated
NHERF1(Ser) were regulated by the phosphatase activity of
PRL-3, we transfected B16F1 cells with a PRL-3-expressing
plasmid or transfected B16BL6 cells with PRL-3 siRNA. PRL-3
overexpression led to a decrease in the levels of phosphory-
lated NHERF1(Ser), whereas PRL-3 interference did the
reverse (Figure 5c), indicating that NHERF1 could be a
substrate of PRL-3. Using IF colocalization and IP assays, we
conﬁrmed the interaction between PRL-3 and NHERF1 in the
nucleus of B16F1 cells transfected with myc-PRL-3-expressing
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plasmids (Supplementary Figure S6 online). In addition,
B16F1 cells were transfected with PRL-3 (C104S), a loss-of-
function mutant. Unlike wild-type PRL-3, PRL-3 (C104S) over-
expression failed to decrease the levels of phosphorylated
NHERF1(Ser) (Figure 5d). It also failed to promote the
translocation of NHERF1 and PTEN from the nucleus to the
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cytoplasm (Figure 5e). Taken together, PRL-3 could trigger the
dephosphorylation of NHERF1 in the nucleus and promote
the translocation of dephosphorylated NHERF1 from the
nucleus to the cytoplasm.
Targeting NHERF1 has therapeutic signiﬁcance in highly
malignant melanoma
To verify the importance of NHERF1 as a mediator in highly
malignant melanoma with high levels of PRL-3, we examined
Figure 4. Phosphatase of regenerating liver-3 (PRL-3) promotes the translocation of NHERF1 from the nucleus to the cytoplasm. (a and b) PRL-3 was
overexpressed in B16F1 cells and knocked down in B16BL6 cells. Forty-eight hours after transfection, cellular localization of the endogenous NHERF1 (red) and
PTEN (green) was detected by confocal immunoﬂuorescence microscopy (a), and the protein levels of NHERF1 and PTEN in the cytoplasm and the nucleus were
detected by WB (b). The overlay is indicated by yellow. (c and d) PRL-3 was overexpressed in human melanoma A375 cells and knocked down in A875 cells,
respectively. Forty-eight hours after transfection, the protein levels of NHERF1 and PTEN in whole cell lysate (c, above), cytoplasm, and nucleus were detected by
WB (c, below). The endogenous NHERF1 (red) and PTEN (green) were detected by confocal immunoﬂuorescence microscopy (d). (e) B16F1 cells were co-
perturbed with PRL-3/siNHERF1, and B16BL6 cells were co-perturbed with siPRL-3/NHERF1. Forty-eight hours later, the transfection efﬁciency (left) and the
cellular localization of NHERF1 and PTEN (right) were determined by WB. Data are the mean± SEM of three independent experiments. *Po0.05 and **Po0.01.
Scale bar=50 μm.
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the anti-tumor efﬁciency of targeting NHERF1. B16BL6 cells
were transfected with NHERF1 siRNA, and B16F1 cells in
which NHERF1 expression was knocked down were used as a
control. Knocking down NHERF1 signiﬁcantly inhibited the
growth rate of B16BL6 but not B16F1 cells (Figure 6a). When
these cells (1× 106 cells/mice) were injected subcutaneously
into the right ﬂank of C57BL/6 mice, it was found that
knocking down NHERF1 also inhibited the tumor growth in
the mice inoculated with the transfected B16BL6 cells
(Figure 6b). The overall survival of the tumor-bearing mice
inoculated with the transfected B16BL6 cells was prolonged
signiﬁcantly when NHERF1 expression was knocked down
(Figure 6c). However, such a phenomenon did not exist in
B16F1 cells.
DISCUSSION
In this study, we examined the mechanism by which PRL-3
promotes the malignant progression of melanoma cells. A
scaffold protein, NHERF1, was determined to be a potential
substrate of PRL-3, and it was shown to mediate the tumor
progression promoted by PRL-3.
B16F1, B16F10, and B16BL6 cells are homogenous
melanoma cells with gradually increasing malignancy. To
understand the underlying molecular mechanisms during
the malignant progression of melanoma cells, we need
more accurately progressed and successive cell lines. For
this purpose, a series of B16 melanoma cell lines with
gradually increasing degrees of malignancy (B16F2-F9) were
generated in our laboratory to be used in addition to the
commercial B16F1, B16F10, and B16BL6 cells. By using
these successive cell lines, we concluded that PRL-3 must be
involved in the change in cellular functions including,
increased proliferation, adhesion, migration, and invasion.
The activation of the Akt signaling pathway has been
known as an important event during the malignant progres-
sion of tumor cells (Zhang et al., 2014). Through a series of
comparisons, we found that the phosphatase activity but
not the expression level of PTEN in B16F1 cells was higher
than B16BL6 cells, resulting in lower levels of pAkt in
B16F1 cells. PTEN is an important negative regulator of the
Akt activation, and the loss or mutation of PTEN usually
results in tumorigenesis (Carracedo et al., 2011). However, no
PTEN mutation was found in the series of B16 melanoma
cell lines.
Traditional views suggest that PTEN functions at the cell
membrane to inhibit PI3K-Akt signaling. The function of
nuclear PTEN as tumor-suppressor has been widely reported
(Baker, 2007; Planchon et al., 2008; Jang et al., 2010;
Wrighton, 2011), but none of these reports suggest a
relationship between PTEN and Akt activity. In this study,
PTEN was observed to colocalize and translocate with
NHERF1 in both melanoma cell lines and human mela-
noma tissues. As reported previously, PTEN can be recruited
by NHERF1 to the cell membrane where it suppresses the
activation of the Akt signaling pathway in glioblastoma cells
(Molina et al., 2012). In the current experiment, we also
conﬁrmed that PTEN interact with NHERF1 in B16BL6 cells,
but it was not recruited by NHERF1 as described in previous
reports.
During the malignant progression of melanoma cells, it
should be noted that co-localized NHERF1 and PTEN showed
an obvious trafﬁcking direction from the nucleus to the
cytoplasm. Namely, PTEN translocated from the nucleus to
the cytoplasm following NHERF1, and then it was sequestered
in the cytoplasm by NHERF1. Analysis showed that phos-
phorylated Akt mostly accumulated in the nucleus in B16
melanoma cells, and the nuclear accumulation of PTEN
decreased the level of pAkt. Therefore, the cytoplasmic
translocation of PTEN contributes to the increase in pAkt.
These results conﬁrmed that the NHERF1/PTEN interaction
and the nucleus–cytoplasm direction may be a key event
during the malignant progression of melanoma. The next
question is to determine what promotes the cytoplasmic
translocation of NHERF1.
Considering that the expression of PRL-3 also increased
gradually during the malignant progression of melanoma
cells, we examined the relationship between PRL-3 and
NHERF1. The association of PRL-3 and NHERF1 is theoreti-
cally possible as they were both reported to interact with
ezrin (Reczek et al., 1997; Forte et al., 2008). Our results
indicated that PRL-3 determined the cellular location of
the NHERF1–PTEN interaction. The overexpression of PRL-3
greatly increased the NHERF1–PTEN interaction in the
cytoplasm, whereas no interaction was observed in the
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Figure 6. NHERF1 interference exerts anti-tumor therapeutic effects in a
mouse model of highly malignant melanoma. (a) B16F1 and B16BL6 cells
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proliferation rate was examined for 72 hours by the MTT assay. (b) B16F1 and
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Twenty-four hours later, the treated cells (1×106) were injected
subcutaneously into the right ﬂank of C57BL/6 mice, and the tumor volumes
were recorded. (c) The survival statistics of mice in each group were recorded.
The survival rate equals to the percentage of live tumor-bearing mice among
the total mice (n=14 per group) at the indicated time point. Data are the
mean± SEM of three independent experiments. **Po0.01.
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nucleus. By contrast, the interference of PRL-3 decreased the
interaction in the cytoplasm but not in the nucleus.
On the basis of the existing knowledge, NHERF1 can be
regulated by phosphorylation at serine and threonine sites.
The results obtained in the present study show that the
phosphorylation of NHERF1(Ser) is higher in B16F1 cells than
in B16BL6 cells. Interestingly, we found that PRL-3 inhibited
the phosphorylation of NHERF1(Ser) in melanoma cells.
These data suggest that the cytoplasmic translocation of
NHERF1 from the nucleus depends on the de-phos-
phorylation of NHERF1, which can be promoted by PRL-3.
Consistent with previous reports, cytoplasmic NHERF1
seems to act as an oncogenic protein. Upon NHERF1
interference in B16BL6 cells, tumor growth was signiﬁcantly
inhibited both in vitro and in vivo, and the survival rate of
tumor-bearing mice increased. However, the effect of
NHERF1-interference on B16F1 cells was scarcely evident.
Such a different response between B16F1 and B16BL6 cells
further certiﬁed the oncogenic role of cytoplasmic NHERF1.
These results suggest that cytoplasmic NHERF1 may serve as a
therapeutic target for malignant tumor growth and metastasis.
Taken together, our study provides a unique insight into
melanoma metastasis and a diagnostic marker for malignant
melanoma. PRL-3 regulates the phosphorylation of NHERF1
at its serine site and promotes its cytoplasmic translocation,
which further promotes the cytoplasmic translocation of PTEN
and results in the upregulation of pAkt. Cytoplasmic NHERF1
can serve as a diagnostic marker and a good therapeutic target
for malignant melanoma. It further highlights the signiﬁcance
of rational targeted therapy.
MATERIALS AND METHODS
Reagents
DMEM, MEM, fetal bovine serum (FBS), and lipofectamine 2000
were purchased from Life Technologies (Carlsbad, CA). MTT and
type IV collagenase were purchased from Sigma-Aldrich (St Louis,
MO). Western blotting/immunoprecipitation lysis buffer was
obtained from Beyotime (Nantong, China). D-Luciferin Fireﬂy
Potassium Salt was obtained from Xenogen (Alameda, CA). PTEN-
speciﬁc inhibitor bpV (Hopic) was purchased from Merck Bioscience
(Bad Soden, Germany). Antibodies to pAkt (S473) (D9E), Akt, Lamin
B1 (D4Q4Z), GAPDH (14C10), HA-Tag (6E2), and Flag-Tag were
obtained from Cell Signaling Technology (Beverly, MA). Protein A/G
PLUS-Agarose, antibodies to β-Actin, p-Ser (16B4), and p-Thr (H-2)
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Antibodies to PRL-3, NHERF1, and PTEN (Y184) were purchased
from Abcam (Cambridge, UK). Fixation buffer and 1×Phosﬂow
Perm Buffer were from BD Biosciences (San Diego, CA). NE-PER
Nuclear and Cytoplasmic Extraction Reagents were obtained from
Thermo (Rockford, IL). The Real Envision Detection kit was the
product of GeneTech Company (Nanjing, China). Melanoma tissue
arrays were purchased from US Biomax (Rockville, MD). All other
chemicals were obtained from Sigma-Aldrich (St Louis, MO).
Animals
Six-week-old female C57BL/6 mice were purchased from Academy
of Military Medical Sciences (Beijing, China). They were maintained
with free access to pellet food and water in plastic cages at 21± 2 °C
and kept on a 12-h light/dark cycle. All efforts were made to
minimize the animals’ suffering and to reduce the number of animals
used. The medical ethical committee of Nanjing University approved
all described studies. The study was conducted according to the
Declaration of Helsinki Principles.
Cell culture
Mouse melanoma B16F1, B16F10, and B16BL6 cells and human
melanoma A375, A875, and M14 cells were obtained from the
Shanghai Institute of Cell Biology (Shanghai, China) and were
maintained in DMEM supplemented with 10% FBS plus 2 mM
glutamine, 100 U/ml penicillin, and 100mg/ml streptomycin.
B16F10-luc cells were obtained from Cold Spring Biotech Corp.
(Taipei, Taiwan). B16F2, F3, F4, F5, F6, F7, F8, and F9 cells were
generated in our laboratory by repeated i.v. injection of B16
melanoma cells as previously described (Fidler, 1975).
Small animal in vivo imaging system
B16F10-Luc cells in the exponential growth phase were harvested by
trypsinization and washed twice before injection. Cells were injected
into the right hind footpads of C57BL/6 mice. Twenty days after
inoculation, each mouse was injected with the luciferase substrate
(D-Luciferin Fireﬂy Potassium Salt, 15mg/ml, 100 μl). In vivo
ﬂuorescent images of all mice were taken within 1 h. Luminescence
statistics were recorded.
Vector construction
HA-NHERF1, Flag-PTEN-WT, and Flag-PTEN-△PDZ were generated
as described in supplementary materials online. The following
plasmids were constructed as previously described: pTARGET-Myc-
PRL-3, pRNA-U6.1/Neo-Luc-siRNA, pRNA-U6.1/Neo-Luc-PRL-3-
siRNA, pIERS2-EGFP, and pIERS2-EGFP-PRL-3 (Qian et al., 2007;
Wang et al., 2009).
Statistical analysis
Data are expressed as mean+/− SEM. Student’s t test and the
one-way ANOVA test were used for statistical analyses of the data.
All statistical analyses were conducted using SPSS 10.0 statistical
software (SPSS, Chicago, IL). Cases in which P values ofo0.05 were
considered statistically signiﬁcant.
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